Contact Us

Phone: 1-866-61-EISAI (1-866-61-34724)

Fax: 1-866-57-EISAI (1-866-57-34724)

Monday - Friday 8AM - 8PM ET


Coding & Pricing
Billing Forms

ICD-9-CM Supplementary Classification Codes

Supplemental classification codes permit the reporting of circumstances and conditions that impact the disease or injury. When providers use supplementary ICD-9-CM codes, they should also report an ICD-9-CM code from one of the main chapters of ICD-9-CM, indicating the nature of the condition. Correct coding is the responsibility of the provider submitting a claim for the item or service. Please check with the payor to verify coding or special billing requirements.

Below are ICD-9-CM supplementary classification codes that may be reasonably related to a diagnosis within the product’s approved label.

Other codes may be appropriate. Please see FDA approved indications for ALOXI®.

ICD-9-CM Supplementary Classification Codes CINV Description
E930.7 II Antineoplastic antibiotic causing adverse effects in therapeutic use
E933.1 II Antineoplastic and immunosuppressive drugs causing adverse effects in therapeutic use
V07.39 II Other prophylactic chemotherapy
V07.8 II Need for isolation and other prophylactic measures; need for other specified prophylactic measure
V58.11 II Encounter for other and unspecified procedures and aftercare; encounter for antineoplastic chemotherapy

We recommend verifying a health plan’s coding policies. The Eisai Assistance Program can provide information to patients and healthcare professionals relating to payor-specific policies and can address other questions at: 1-866-61-EISAI or 1-866-61-34724.

Indication

ALOXI® (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.


Important Safety Information:


For more information about ALOXI® please see full Prescribing Information.




Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.

Distributed and marketed by Eisai Inc. CORP74AR6 ©2012 Eisai Inc. All rights reserved.

This site was last modified on : December 19, 2011 at 5:45pm ET